Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 28, 2023 03:30 ET | Source: Philogen

Philogen enters into a Service and Supply Agreement with IBSA for the GMP Production of a Therapeutic Protein

Philogen enters into a Service and Supply Agreement with IBSA for the GMP Production of a Therapeutic Protein Siena, Italy, 28th June 2023 – Philogen S.p.A (BIT: PHIL) today announced that it has...
June 01, 2023 02:30 ET | Source: Philogen

Philogen Announces Clinical Trial Collaboration with MSD

The Phase II clinical trial investigates Philogen's immunocytokines (i) L19IL2 (ii) L19TNF, and (iii) Nidlegy™ in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in stage III and...
May 30, 2023 01:00 ET | Source: Philogen

Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand

Mumbai, India and Siena, Italy, 30th May 2023 – Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or...
May 25, 2023 02:00 ET | Source: Philogen

Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich

Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich L19TNF (also known as Fibromun) is an...
November 07, 2022 11:07 ET | Source: Philogen

Philogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands isolated from DNA-Encoded Chemical Libraries

Philogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands isolated from DNA-Encoded Chemical Libraries The study highlights the application of DNA-Encoded Chemical...
July 25, 2022 08:00 ET | Source: Philogen

Philogen announces enrolment of 214 patients in the Nidlegy™ Phase III European clinical trial for the treatment of locally advanced melanoma

Philogen announces enrolment of 214 patients in the Nidlegy™ Phase III European clinical trial for the treatment of locally advanced melanoma 214 patients recruited in the study, in line with...
November 24, 2021 03:00 ET | Source: Philogen

PHILOGEN ANNOUNCES NEW COLLABORATION WITH JANSSEN TO DISCOVER SMALL MOLECULE THERAPEUTICS

PHILOGEN ANNOUNCES NEW COLLABORATION WITH JANSSEN TO DISCOVER SMALL MOLECULE THERAPEUTICS Siena, Italy, November 24, 2021 - Philogen S.p.A., a clinical-stage biotechnology company focused on antibody...
November 12, 2021 02:00 ET | Source: Philogen

Philogen Provides Corporate Update

Philogen Provides Corporate Update Nidlegy™ and Fibromun are on track with planned timelines in pivotal clinical trialsFibromun shows potent activity in last-line glioblastoma in combination with...
September 29, 2021 04:58 ET | Source: Philogen

Philogen Provides Corporate Update

Philogen Provides Corporate Update Nidlegy™ and Fibromun on track with planned timelines in pivotal clinical trialsUse of Nidlegy™ in non-melanoma skin cancer expanded in Phase II clinical...
May 12, 2021 13:00 ET | Source: Philogen

Philogen Announces First Quarter 2021 Results and Provides Update on Pipeline Progress

Philogen Announces First Quarter 2021 Results and Provides Update on Pipeline Progress May 12, 2021 NidlegyTM on track for Phase III European trial in stage IIIB/C melanoma. Opening of additional...